Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) just unveiled an announcement.
Shanghai Fosun Pharmaceutical has established a Strategic Committee under its board of directors to bolster its strategic development and decision-making processes. This committee is tasked with examining the company’s mid and long-term development strategies, significant investment decisions, and other material issues affecting its growth. By reinforcing the scientific nature of decision-making and improving corporate governance, the company aims to enhance investment benefits and decision quality, thereby strengthening its industry positioning.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, operating in the pharmaceutical industry. The company focuses on developing and manufacturing a wide range of pharmaceutical products and services, with a market emphasis on enhancing its core competitiveness and strategic development.
Average Trading Volume: 7,025,116
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.06B
See more data about 2196 stock on TipRanks’ Stock Analysis page.